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A B S T R A C T   
Background: Aluminium salts are the most common adjuvants in infant vaccines. The aluminium content of a 
vaccine is provided by the manufacturer and is indicated on the patient information leaflet. There is no inde-
pendent verification, for example by the European Medicines Agency, of the aluminium content of infant 
vaccines. 
Methods: We have measured the aluminium content of thirteen infant vaccines using microwave-assisted acid and 
peroxide digestion followed by transversely heated graphite furnace atomic absorption spectrometry. Our data 
are compared with manufacturer’s data using full statistical analyses including Bayesian methods. 
Results: We found that only three vaccines contained the amount of aluminium indicated by the manufacturer. 
Six vaccines contained a statistically significant (P < 0.05) greater quantity while four vaccines contained a 
statistically significant (P < 0.05) lower quantity. The range of content for any single vaccine varied consider-
ably, for example, from 0.172 to 0.602 mg/vaccine for Havrix. 
Conclusions: The data have raised specific questions about the significance of the aluminium content of vaccines 
and identified areas of extremely limited information. Since aluminium is a known toxin in humans and spe-
cifically a neurotoxin, its content in vaccines should be accurate and independently monitored to ensure both 
efficacy and safety.   
1. Introduction 
Aluminium salts are the adjuvants of choice in the majority of 
inactivated paediatric vaccines. Their presence at injection sites 
following vaccination results in the activation of humoral immunity. 
This pathway is characterised by the differentiation of naive CD4+ T 
cells into Th2 effector subsets and the subsequent enhancement of 
antigen-specific antibody titres [1–5]. T cell priming post-vaccination 
occurs following the cross-presentation of antigen-MHC complexes by 
immunocompetent phagocytes and occurs exclusively within draining 
lymph nodes [6] at locations often distant from the injection site. 
Aluminium adjuvants have been shown to facilitate this process by; i) 
actively increasing levels of antigen recognition and uptake by 
antigen-presenting cells [7–9], ii) acting in a protective capacity to 
prevent antigen degradation within intracellular compartments [9,10] 
and (iii) amplifying and sustaining antigen-MHC II expression by 
antigen-presenting cells [9,11,12]. Other suggested mechanisms un-
derlying the immunostimulatory effects of aluminium adjuvants include 
the secretion of pro-inflammatory cytokines by activated 
antigen-presenting cells [13–17] and the formation of an ‘antigen depot’ 
at the vaccine injection site [18,19]. While the latter is regarded by some 
as superfluous to the mechanism of action of aluminium adjuvants, 
recent evidence has demonstrated that extracellular traps formed by 
neutrophils following immunization make a significant contribution to 
their immunological activity in vivo [20]. However, the modus operandi 
of aluminium adjuvants remains to be fully elucidated [21,22]. 
Three aluminium salts are currently used as adjuvants in human 
vaccines. Two of these, aluminium oxyhydroxide (available commer-
cially as Alhydrogel®) and aluminium hydroxyphosphate (available 
commercially as AdjuPhos®) have been widely studied while the third, 
aluminium hydroxyphosphate sulphate, is proprietary to Merck and has 
not been available for independent scrutiny [22,23]. The type and 
amount of aluminium adjuvant used in paediatric vaccines is made 
available through patient information leaflets, see the manufacturer’s 
information summarised in Table 1. The information given is, at best, 
vague. Descriptions of aluminium salts are often inaccurate, for 
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example, the use of the term aluminium hydroxide when the form of 
aluminium included is aluminium oxyhydroxide. Quantitative data 
describing the content of aluminium in a vaccine is often presented in a 
number of different formats. For example, all do present these data as 
total aluminium but some additionally present the data in respect of the 
weight of aluminium salt. This practice is confusing for anyone reading 
the patient information leaflet. The manufacturers’ stated content of 
aluminium in vaccines listed in Table 1 varies from 0.125 (Prevnar 13) 
to 0.85 (PEDIARIX) mg per 0.5 mL dose of vaccine though little or no 
information is available as to why the content is so varied. Why does one 
vaccine require more aluminium adjuvant to be effective than another? 
There exists a non-regulatory limit of 1.25 mg aluminium per dose of 
vaccine based upon maximum titres of antibodies produced. However, 
even this may be exceeded under certain circumstances. The European 
Medicines Agency (EMA) and the Food and Drug Administration (FDA) 
are charged with the responsibility of verifying the information pro-
vided by vaccine manufacturers in their patient information leaflets. 
When questioned repeatedly on this subject (for example, EMA request 
reference ASK-56123) neither organisation was able to confirm that they 
routinely measure the aluminium content of vaccines. They indicated 
that they relied upon data provided to them by manufacturers, though 
no such data were forthcoming following requests including freedom of 
information act requests to the FDA (For example, FOIA Requests 
2019-11150 to 2019-11156 & 2019-11158). When the EMA was asked, 
which analytical methods were used by either their organisation or 
vaccine manufacturers to measure the aluminium content of vaccines, 
they replied that this was proprietary information and could not be 
provided (EMA request reference ASK-56707). It would appear that the 
aluminium content of a vaccine is only measured by the manufacturer, 
using an unspecified method, and that these data are not made publicly 
available. 
One piece of important information about the aluminium content of 
a vaccine is that it is clearly critical. Why else would there be such a wide 
range of contents used across the paediatric vaccine schedule. Since 
those charged with ensuring that the information provided by vaccine 
manufacturers is correct are seemingly choosing to neglect this re-
sponsibility, herein we have measured the aluminium content of thir-
teen paediatric vaccines. We find that the measured content of 
aluminium is only similar to that given by the manufacturer in three out 
of thirteen vaccines. 
2. Materials and methods 
2.1. Vaccines 
Whole vaccines were provided under license by a state registered 
paediatrician. All vaccines were in their original packaging and 
remained pristine and refrigerated at 4 ◦C until use. 
2.2. Digestion of vaccines 
Each whole vaccine was added to an acid-washed, dried and labelled 
20 mL PFA Teflon MARSXpress digestion vessel closed with a venting 
plug and screw cap (CEM Technology, UK). The idea being that the 
whole vaccine was ‘injected’ into the digestion vessel in the identical 
manner as it would be used in human vaccination. In each case, it was 
assumed, though it was unlikely to be the case, that the whole vaccine 
volume of 0.5 mL was transferred to the digestion tube. To each whole 
vaccine, 1 mL of concentrated HNO3 (Analar, 15.8 M Fisher Scientific, 
UK) and 1 mL 30 % w/v H2O2 (Aristar, BDH, UK) were added and the 
mixture subjected to microwave-assisted digestion (MARS6 CEM, One 
Touch Technology, UK). The resulting digests were further diluted by 
the addition of 2.5 mL of pure water (conductivity <0.067μS/cm) and 
stored appropriately for subsequent analyses. Method blanks were pre-
pared where 0.5 mL of pure water was substituted for the whole vaccine. 
Full information pertaining to this method of sample digestion including 
microwave parameters are available elsewhere [24]. 
Table 1 
Information relating to each of the thirteen infant vaccines taken directly from their patient information leaflets respectively.  
Trade name of 
vaccine 
Pharmaceutical company 
[Country of manufacture] 
Paediatric 
dose (mL) 
Manufacturer’s stated aluminium 
content per paediatric dose (mg) 
Infant age 
range 
Manufacturer’s description of vaccine 
PEDIARIX GlaxoSmithKline (GSK) 
[Belgium] 
0.5 "not more than 0.85 mg aluminium" from 2 to 6 
months 
Vaccine for the active immunization against 
diphtheria, tetanus, pertussis, hepatitis B virus 
infection and poliomyelitis. 
Pentacel Sanofi Pasteur [Canada] 0.5 0.33 mg of aluminium as 1.5 mg 
aluminium phosphate 
from 6 weeks 
to 4 years 
Vaccine for the active immunization against 
diphtheria, tetanus, pertussis, poliomyelitis and 
disease caused by Haemophilus influenzae type b. 
ENGERIX-B GlaxoSmithKline (GSK) 
[Belgium] 
0.5 0.25 mg of aluminium as aluminium 
hydroxide 
from 1 to 6 
months 
Vaccine for immunization against infection caused by 
hepatitis B virus. 
Prevnar 13 Pfizer [United States] 0.5 0.125 mg of aluminium (as 
aluminium phosphate) 
from 6 weeks 
to 5 years 
Vaccine for active immunization against disease 
caused by Streptococcus pneumoniae. 
PedvaxHIB Merck & Co., Inc [United 
States] 
0.5 0.225 mg of aluminium as 
amorphous aluminium 
hydroxyphosphate sulphate 
from 6 to 11 
months 
Vaccine for immunization against infection caused by 
Haemophilus influenzae type b. 
KINRIX GlaxoSmithKline (GSK) 
[Belgium] 
0.5 "not more than 0.6 mg aluminium by 
assay" 
from 4 up to 6 
years 
Vaccine for immunization against diphtheria, 
tetanus, pertussis and poliomyelitis. 
INFANRIX GlaxoSmithKline (GSK) 
[Belgium] 
0.5 "not more than 0.625 mg aluminium 
by assay" 
from 6 weeks 
up to 6 years 
Vaccine for active immunization against diphtheria, 
tetanus and pertussis. 
BOOSTRIX GlaxoSmithKline (GSK) 
[Belgium] 
0.5 "not more than 0.39 mg aluminium 
by assay" 
from 10 years Vaccine for active immunization against tetanus, 
diphtheria and pertussis. 
VAQTA Merck & Co., Inc [United 
States] 




months (up to 
18 years) 
Vaccine for immunization against disease caused by 
hepatitis A virus 
Adacel Sanofi Pasteur [Canada] 0.5 1.5 mg aluminium phosphate 
(0.33 mg aluminium) 
from 10 years Vaccine for active immunization against tetanus, 
diphtheria and pertussis. 
HAVRIX GlaxoSmithKline (GSK) 
[Belgium] 
0.5 0.25 mg of aluminium as aluminium 
hydroxide 
from 12 to 24 
months 
Vaccine for immunisation against disease caused by 
hepatitis A virus. 
Infanrix hexa GlaxoSmithKline (GSK) 
[Belgium] 
0.5 0.82 mg of aluminium (as 
aluminium salts) 
from 2 to 18 
months 
Vaccine for immunization against diphtheria, 
tetanus, pertussis, hepatitis B, poliomyelitis and 
Haemophilus influenzae type b. 
Synflorix GlaxoSmithKline (GSK) 
[Belgium] 
0.5 0.5 mg of aluminium as aluminium 
phosphate 
from 6 weeks 
up to 5 years 
Vaccine for immunization against infections caused 
by Streptococcus pneumoniae.  
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2.3. Determination of aluminium 
The total aluminium content of each vaccine digest and each method 
blank was measured by transversely heated graphite furnace atomic 
absorption spectrometry (TH GFAAS) using a fully established method 
including matrix-matched standards and commensurate quality assur-
ance criteria [24]. Method blank data equating to 54 ngAl/5 mL digest 
were subtracted from each vaccine sample. Data are presented as 
mgAl/0.5 mL vaccine volume. 
2.4. Statistics 
Data on the measured concentrations of aluminium, stratified by 
brand, were tested for normality. Depending on whether the data were 
normally distributed or not, means and medians were calculated and 
tested two- and one-sided against the manufacturer’s content of 
aluminium (see Table 1) using one-sample t-test and Wilcoxon signed 
rank test respectively. 
Differences in aluminium content between lots were analysed for 
those vaccines with two lots and sufficient sample numbers. 
To determine the probability, expressed as a percentage, that the 
measured content of aluminium in a vaccine was less than, the same as 
or greater than the amount given by the vaccine manufacturer, Bayesian 
methodology was used [25]. 
The hypotheses tested were as follows: 
H0. Declared content of aluminium is equal to or less than the 
measured concentrations of aluminium. (The difference in means is 
zero.) 
The alternative hypothesis is that the difference in means is not zero: 
Ha1. Measured concentration of aluminium is not the same. 
Ha2. Measured concentration of aluminium is greater. 
Ha3. Measured concentration of aluminium is less. 
Tests were repeated one-sided in both directions. For two-sided tests, 
a p-value < 0.05 was considered as statistically significant and for one- 
sided tests a p-value < 0.025. 
Analyses were performed using R-Studio version 1.1.1093 [26] 
including packages ggplot2 [27], doBy [28], BEST [29], BayesianFirst-
Aid [30] and bayesWilcoxTest [31]. The last three packages provide 
Bayesian alternatives to the classical hypothesis tests in R. Bayesian 
methods were used to calculate the percentage probability that 
measured aluminium concentrations were randomly the same or 
greater/less than amounts stated by the manufacturer. Bayes factors can 
complement p-values by providing additional information for hypoth-
esis testing by quantifying the relative evidence for both alternative and 
null hypotheses. Moreover, the magnitude of this evidence can be pre-
sented as percentages [25,32–36]. 
The following code was used to produce random data sets of 
aluminium values for each vaccine with the stated manufacturers mean 
and 10 % RSD. The latter to reflect ‘expected’ manufacturing error.  
rnorm2 <- function(n,mean,sd) {mean + sd*scale(rnorm(n))}                       
The Bayesian approach was repeated with the random data sets 
including the 10 % variation. 
3. Results 
3.1. Pentacel 
The data for Pentacel were normally distributed. Ten individual 
vaccines were investigated across two lots. The aluminium content 
differed significantly between lots (P < 0.030). The highest content of 
aluminium measured was 0.440 mg/vaccine. The lowest content of 
aluminium measured was 0.343 mg/vaccine. The mean content of ten 
vaccines was 0.379 mg/vaccine (Table 2). The aluminium content of 
Pentacel was significantly higher for both lots combined (P < 0.001) 
(Fig. 1), lot 1 only (P = 0.005) and lot 2 only (P = 0.004) than the 
amount stated by the manufacturer (0.330 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.2. Havrix 
The data for Havrix were not normally distributed. Twenty individ-
ual vaccines were investigated across two lots. The aluminium content 
differed significantly between lots (P < 0.001). The highest content of 
aluminium measured was 0.602 mg/vaccine. The lowest content of 
aluminium measured was 0.172 mg/vaccine. The median content of 
twenty vaccines was 0.307 mg/vaccine (Table 2). The aluminium con-
tent of Havrix was significantly higher for both lots combined 
(P = 0.003) (Fig. 1) and lot 2 only (P = 0.003) than the amount stated by 
the manufacturer (0.250 mg/vaccine) on the patient information leaflet 
(Table 3). 
3.3. Adacel 
The data for Adacel were not normally distributed. Nine individual 
vaccines were investigated across two lots. The aluminium content was 
not significantly different between lots (P > 0.05).The highest content of 
aluminium measured was 0.445 mg/vaccine. The lowest content of 
aluminium measured was 0.302 mg/vaccine. The median content of 
nine vaccines was 0.397 mg/vaccine (Table 2). The aluminium content 
of Adacel was significantly higher (P = 0.006) (Fig. 1) than the amount 
stated by the manufacturer (0.330 mg/vaccine) on the patient infor-
mation leaflet (Table 3). 
3.4. Boostrix 
The data for Boostrix were normally distributed. Twenty individual 
vaccines were investigated from a single lot. The highest content of 
aluminium measured was 0.525 mg/vaccine. The lowest content of 
aluminium measured was 0.345 mg/vaccine. The mean content of 
twenty vaccines was 0.407 mg/vaccine (Table 2). The aluminium con-
tent of Boostrix was not significantly different (P = 0.101) (Fig. 1) to the 
amount stated by the manufacturer (0.390 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.5. EngerixB 
The data for EngerixB were normally distributed. Twenty individual 
Table 2 
Descriptive statistics for each of the thirteen infant vaccines including normal 
distribution (N.D.), number of replicates (N), minimum (Min.), maximum 
(Max.), mean/median values (mg/0.5 mL dose) and indication of variance (SD, 
RSD). Vaccines ordered according to their mean/median Al contents.  
Vaccine N.D. N Min. Max. Mean/ 
Median 
SD RSD 
Prevnar 13 Y 6 0.127 0.141 0.136 0.006 0.04 
EngerixB Y 20 0.187 0.287 0.249 0.027 0.11 
Pedvax Y 20 0.192 0.334 0.287 0.040 0.14 
Havrix N 20 0.172 0.602 0.307 0.084 0.28 
Vaqta N 20 0.270 0.796 0.340 0.109 0.32 
Pentacel Y 10 0.343 0.440 0.379 0.032 0.09 
Adacel N 9 0.302 0.445 0.397 0.041 0.10 
Synflorix Y 3 0.396 0.399 0.398 0.002 0.00 
Boostrix Y 20 0.345 0.525 0.407 0.043 0.11 
Kinrix N 20 0.464 0.635 0.511 0.062 0.12 
Infanrix Y 20 0.415 0.662 0.546 0.069 0.13 
Pediarix Y 20 0.575 0.743 0.661 0.039 0.06 
Infanrix Hexa Y 6 0.766 0.851 0.806 0.028 0.04  
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vaccines were investigated from a single lot. The highest content of 
aluminium measured was 0.287 mg/vaccine. The lowest content of 
aluminium measured was 0.187 mg/vaccine. The mean content of 
twenty vaccines was 0.249 mg/vaccine (Table 2). The aluminium con-
tent of EngerixB was not significantly different (P = 0.897) (Fig. 1) to the 
amount stated by the manufacturer (0.250 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.6. Infanrix 
The data for Infanrix were normally distributed. Twenty individual 
vaccines were investigated from a single lot. The highest content of 
aluminium measured was 0.662 mg/vaccine. The lowest content of 
aluminium measured was 0.415 mg/vaccine. The mean content of 
twenty vaccines was 0.546 mg/vaccine (Table 2). The aluminium con-
tent of Infanrix was significantly lower (P < 0.001) (Fig. 1) than the 
amount stated by the manufacturer (0.625 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.7. Infanrix Hexa 
The data for Infanrix Hexa were normally distributed. Six individual 
vaccines were investigated from a single lot. The highest content of 
aluminium measured was 0.851 mg/vaccine. The lowest content of 
aluminium measured was 0.766 mg/vaccine. The mean content of six 
vaccines was 0.806 mg/vaccine (Table 2). The aluminium content of 
Infanrix Hexa was not significantly different (P = 0.268) (Fig. 1) to the 
amount stated by the manufacturer (0.820 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.8. Kinrix 
The data for Kinrix were not normally distributed. Twenty individual 
vaccines were investigated across two lots. The aluminium content was 
not significantly different between lots (P > 0.05). The highest content 
of aluminium measured was 0.635 mg/vaccine. The lowest content of 
aluminium measured was 0.464 mg/vaccine. The median content of 
twenty vaccines was 0.511 mg/vaccine (Table 2). The aluminium con-
tent of Kinrix was significantly less (P = 0.001) (Fig. 1) than the amount 
stated by the manufacturer (0.600 mg/vaccine) on the patient infor-
mation leaflet (Table 3). 
3.9. Pediarix 
The data for Pediarix were normally distributed. Twenty individual 
vaccines were investigated across two lots. The aluminium content was 
not significantly different between lots (P > 0.05). The highest content 
of aluminium measured was 0.743 mg/vaccine. The lowest content of 
aluminium measured was 0.575 mg/vaccine. The mean content of 
twenty vaccines was 0.661 mg/vaccine (Table 2). The aluminium con-
tent of Pediarix was significantly lower (P < 0.001) (Fig. 1) than the 
amount stated by the manufacturer (0.850 mg/vaccine) on the patient 
Fig. 1. Boxplots of measured aluminium concentrations (mg/0.5 mL dose) stratified per vaccine brand and compared to the manufacturers’ stated amounts (yellow 
line). The colour gradient represents p-values of one-sided t-tests or Mann-Whitney U tests of the measured Al against the manufacturers’ stated amounts. The red 
boxplots indicate vaccines with significantly more aluminium than that stated by the manufacturer. Boxplots in violet and blue represent data for vaccines where the 
measured content is either not significantly to or significantly less than the manufacturers’ stated amounts. (For interpretation of the references to colour in this 
figure legend, the reader is referred to the web version of this article). 
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information leaflet (Table 3). 
3.10. Pedvax 
The data for Pedvax were normally distributed. Twenty individual 
vaccines were investigated across two lots. The aluminium content was 
not significantly different between lots (P > 0.05). The highest content 
of aluminium measured was 0.334 mg/vaccine. The lowest content of 
aluminium measured was 0.192 mg/vaccine. The mean content of 
twenty vaccines was 0.287 mg/vaccine (Table 2). The aluminium con-
tent of Pedvax was significantly higher (P < 0.001) (Fig. 1) than the 
amount stated by the manufacturer (0.225 mg/vaccine) on the patient 
information leaflet (Table 3). 
3.11. Prevnar13 
The data for Prevnar13 were normally distributed. Six individual 
vaccines were investigated in a single lot. The highest content of 
aluminium measured was 0.141 mg/vaccine. The lowest content of 
aluminium measured was 0.127 mg/vaccine. The mean content of six 
vaccines was 0.136 mg/vaccine (Table 2). The aluminium content of 
Prevnar13 was significantly higher (P = 0.003) (Fig. 1) than the amount 
stated by the manufacturer (0.125 mg/vaccine) on the patient infor-
mation leaflet (Table 3). 
3.12. Synflorix 
The data for Synflorix were normally distributed. Three individual 
vaccines were investigated from a single lot. The highest content of 
aluminium measured was 0.399 mg/vaccine. The lowest content of 
aluminium measured was 0.396 mg/vaccine. The mean content of three 
vaccines was 0.398 mg/vaccine (Table 2). The aluminium content of 
Synflorix was significantly less (P < 0.001) (Fig. 1) than the amount 
stated by the manufacturer (0.500 mg/vaccine) on the patient infor-
mation leaflet (Table 3). 
3.13. Vaqta 
The data for Vaqta were not normally distributed. Twenty individual 
vaccines were investigated across two lots. The aluminium content was 
not significantly different between lots (P > 0.05). The highest content 
of aluminium measured was 0.796 mg/vaccine. The lowest content of 
aluminium measured was 0.270 mg/vaccine. The median content of 
twenty vaccines was 0.340 mg/vaccine (Table 2). The aluminium con-
tent of Vaqta was significantly higher (P < 0.001) (Fig. 1) than the 
amount stated by the manufacturer (0.225 mg/vaccine) on the patient 
information leaflet (Table 3). 
4. Discussion 
We present the aluminium content of 13 paediatric vaccines (Sup-
plementary Table 1). We have compared our raw data with values given 
by manufacturers on patient information leaflets. In addition, we have 
applied a generous ±10 % margin of manufacturing error to the latter 
published values when applying Bayesian methods (see Supplementary 
Table 2). Using a level of statistical significance of P = 0.05, 3 vaccines 
contained the amount of aluminium stated by the manufacturer on the 
patient information leaflet (Boostrix, Engerix B, Infanrix Hexa). Six 
vaccines contained significantly more aluminium (Pentacel, Havrix, 
Adacel, Pedvax, Prevnar 13, Vaqta) while 4 vaccines contained signifi-
cantly less (Infanrix, Pediarix, Kinrix, Synflorix). Statistical significance, 
of course, does not tell the only story. For example, while the aluminium 
content of Boostrix is not significantly different to that stated by the 
manufacturer (P > 0.05) there remains a 92 % chance that the 
aluminium content of a Boostrix vaccine will exceed the official content 
(Table 3). In addition, the content of aluminium is extremely variable 
with many vaccines showing %RSD in excess of 10 % even within the 
same lot (Table 2). For example, an infant receiving Havrix could receive 
anything between 0.172 and 0.602 mg of aluminium per vaccine. The 
data presented herein will be an underestimate of the actual content of 
aluminium as it is inevitable that some aluminium adjuvant will remain 
within the syringe system following injection. This will also be true 
when vaccines are injected in vivo. Vaccines that include an aluminium 
adjuvant are cloudy suspensions and manufacturers recommend that 
they are shaken prior to injection. For a few vaccines we were unable to 
obtain ten or more individual products and so data are limited, espe-
cially Synflorix. However, we present the first robust data obtained 
using state-of-the-art methods on the aluminium content of vaccines 
currently being administered in infants. The data are not reassuring. 
They suggest that vaccine manufacturers have limited control over the 
aluminium content of their vaccines. The aluminium content of indi-
vidual vaccines within vaccine lots vary significantly. The amount of 
aluminium an infant receives in a vaccine is, it would appear, akin to a 
lottery. The true significance of this lottery is unknown. Vaccine man-
ufacturers do not provide experimental protocols or rationales to sup-
port the amount of aluminium used in vaccines. If the amount used 
relates to a vaccine’s potency in eliciting antibody titres then this should 
be explained in complementary information including, for example, that 
provided with the vaccine. Equally, how this potency is affected by the 
quantity of aluminium should also be a matter of public record. For 
example, using the data previously noted for Havrix, does it matter for 
the vaccine’s efficacy if the content of aluminium received by an infant 
is 0.172 or 0.602 mg/vaccine. The natural assumption is that it does 
matter, otherwise why state specific amounts of aluminium on patient 
information leaflets. If the vaccine manufacturers stated content of 
aluminium is significant then it is concerning that six of the thirteen 
vaccines measured had statistically higher contents of aluminium. In 
Table 3 
Summary statistics of results including statistical test used (T test or Mann 
Whitney U), two- and one-sided p-values of statistical tests, difference in means 
(stated Al amount – measured amount) and percentage of evidence for the 
outcome according to Bayesian methodology. Vaccines ordered according to 
their mean/median Al content.  
















Prevnar 13 T 0.005 0.003 − 0.01 Greater 0.993 







− 0.06 Greater > 0.999 
Havrix MWU 0.006 0.003 − 0.06 Greater 0.872 
Havrix Lot 1 T 0.710 0.355 − 0.01 Greater 0.661 





− 0.11 Greater 0.995 
Pentacel T 0.001 <
0.001 
− 0.05 Greater 0.999 
Pentacel Lot 
1 
T 0.010 0.005 − 0.03 Greater 0.986 
Pentacel Lot 
2 
T 0.008 0.004 − 0.07 Greater 0.991 
Adacel MWU 0.013 0.006 − 0.07 Greater 0.938 
Synflorix T <
0.001 
1.000 0.10 Same or 
Less 
0.998 
Boostrix T 0.101 0.051 − 0.02 Greater 0.924 















T 0.268 0.866 0.01 Same or 
Less 
0.846  
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practice, this would mean that many infants are receiving significantly 
more aluminium than recommended by the manufacturer. How is this 
additional aluminium affecting the efficacy and safety of the vaccine? 
Similarly, four out of the thirteen vaccines contained statistically 
significantly less aluminium than recommended by the manufacturer. Is 
the lower than prescribed amount of aluminium in these vaccines 
affecting their efficacy? 
The data raise many open questions about the significance of the 
amount of aluminium included in vaccines. They demonstrate if nothing 
else that further clarity and transparency is required from vaccine 
manufacturers as well as regulatory organisations such as the EMA and 
FDA. The aluminium content of a vaccine is never trivial [37]. There is a 
long history of testing the efficacy of childhood vaccines against false 
placebos and warnings against this practice continue to go unheeded 
[38]. It should be a matter of concern that a recent freedom of infor-
mation act request (FOIA Case Number 50882, and HHS Appeal No.; 
19-0083-AA) revealed that the NIH were unable to provide a single 
study relied upon by them in relation to the safety of injection of 
aluminium adjuvants in infants. Human exposure to aluminium is an 
unequivocal consequence of everyday living [39]. Aluminium adjuvants 
in infant vaccines contribute towards the body burden of aluminium 
[37]. Aluminium in the body has the potential to be toxic and signifi-
cantly neurotoxic [40]. Where aluminium is being used for apparent 
human benefit, as in vaccines, we cannot simply ignore the other side of 
the coin, its known toxicity. We cannot afford to be complacent about its 
injection into infants [22]. 
Aluminium adjuvants are critical to the efficacy of vaccines and are 
far from being benign components [22]. Information on their content, 
activity and safety is severely lacking and this void requires urgent 
attention. Until such information is forthcoming, aluminium adjuvants 
remain prime suspects in widely documented vaccination-related 
adverse events. 
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[21] C. Exley, P. Siesjö, H. Eriksson, The immunobiology of aluminium adjuvants: how 
do they really work? Trends Immunol. 31 (2010) 103–109. 
[22] E. Shardlow, M. Mold, C. Exley, Unravelling the enigma: elucidating the 
relationship between the physicochemical properties of aluminium-based 
adjuvants and their immunological mechanisms of action, Allergy Asthma Clin. 
Immunol. 14 (2018) 80. 
[23] M.J. Caulfield, L. Shi, S. Wang, B. Wang, T.W. Tobery, H. Mach, P.L. Ahl, J. 
L. Cannon, J.C. Cook, J.H. Heinrichs, R.D. Sitrin, Effect of alternative aluminum 
adjuvants on the absorption and immunogenicity of HPV16 L1 VLPs in mice, Hum. 
Vaccin. Immunother. 3 (2007) 139–145. 
[24] E. House, M. Esiri, G. Forster, P.G. Ince, C. Exley, Aluminium, iron and copper in 
human brain tissues donated to the medical research council’s cognitive function 
and ageing study, Metallomics 4 (2012) 56–65. 
[25] S.N. Goodman, Introduction to Bayesian methods I: measuring the strength of 
evidence, Clin. Trials 2 (2005) 282–290, discussion 301-304, 364–378. 
[26] R Core Team, R: A Language and Environment for Statistical Computing, R 
Foundation for Statistical Computing, Vienna, Austria, 2020. https://www.R-pro 
ject.org/. 
[27] H. Wickham, W. Chang, L. Henry, T.L. Pedersen, K. Takahashi, C. Wilke, K. Woo, 
H. Yutani, D. Dunnington, ggplot2: Create Elegant Data Visualisations Using the 
Grammar of Graphics, 2020. https://CRAN.R-project.org/package=ggplot2. 
[28] S. Højsgaard, U. Halekoh, doBy: Groupwise Statistics, LSmeans, Linear Contrasts, 
Utilities, 2020. https://CRAN.R-project.org/package=doBy. 
[29] J.K.K. Meredith, J. Kruschke, BEST: Bayesian Estimation Supersedes the t-Test, 
2020. https://CRAN.R-project.org/package=BEST. 
[30] R. Bååth, Bayesian first aid: a package that implements Bayesian alternatives to the 
classical *.Test functions in R, Proceedings of UseR! the International R User 
Conference (2014). https://www.rdocumentation.org/packages/BayesianFirstAi 
d/versions/0.1. 
E. Shardlow et al.                                                                                                                                                                                                                               
Journal of Trace Elements in Medicine and Biology 66 (2021) 126762
7
[31] R. Joachim. bayesWilcoxTest: A Bayesian Alternative to the Wilcoxon Signed Rank 
Test. 20210. R package version 0.1.0. https://rdrr.io/github/joereinhardt/Bayesia 
nFirstAid-Wilcoxon/. 
[32] C. Keysers, V. Gazzola, E.J. Wagenmakers, Using Bayes factor hypothesis testing in 
neuroscience to establish evidence of absence, Nat. Neurosci. 23 (2020) 788–799. 
[33] D.S. Quintana, D.R. Williams, Bayesian alternatives for common null-hypothesis 
significance tests in psychiatry: a non-technical guide using JASP, BMC Psychiatry 
18 (2018) 178. 
[34] S.N. Goodman, Toward evidence-based medical statistics. 1: the P value fallacy, 
Ann. Intern. Med. 130 (1999) 995–1004. 
[35] J. Skinner, Statistics for immunologists, Curr. Protoc. Immunol. 122 (2018) 5436. 
[36] S. Goodman, A dirty dozen: twelve P-value misconceptions, Sem. Hematol. 45 
(2008) 135–140. 
[37] C. Exley, An aluminium adjuvant in a vaccine is an acute exposure to aluminium, 
J. Trace Elem. Med. Biol. 57 (2020) 57–59. 
[38] C. Exley, Aluminium-based adjuvants should not be used as placebos in clinical 
trials, Vaccine 29 (2011) 9289. 
[39] C. Exley, Human exposure to aluminium, Environ. Sci. Process. Impacts 15 (2013) 
1807–1816. 
[40] C. Exley, What is the risk of aluminium as a neurotoxin? Expert Rev. Neurother. 14 
(2014) 589–591. 
E. Shardlow et al.                                                                                                                                                                                                                               
